Hypertension

Chronically improved blood pressure ranks among the most consequential modifiable health risks a person can carry. The causal relationship between blood pressure and cardiovascular harm isn't inferred from associations. It's confirmed by large randomized trials and individual-participant meta-analyses involving hundreds of thousands of people.

BP as a dose-dependent lever

Every 10 mmHg reduction in systolic blood pressure corresponds to roughly 20% fewer major cardiovascular events, 27% fewer strokes, 28% fewer heart failure events, and 13% lower all-cause mortality [1]. That analysis pooled data from 613,815 participants, giving it unusual statistical power. A separate individual-participant data meta-analysis found the benefit in people treated for the first time and those already on medication alike, with approximately 10% fewer events per 5 mmHg reduction. It found no reliable lower threshold below which further reduction stops helping [2].

That last point matters. The older clinical instinct to stop optimizing once someone hits "normal" range isn't well supported by the current evidence base.

How low?

The SPRINT trial randomly assigned high-risk, non-diabetic adults to a systolic target below 120 mmHg versus below 140 mmHg. The intensive group saw roughly 25% fewer cardiovascular events and 27% lower all-cause mortality [3]. Those are large numbers.

The caveats are real, though. Intensive control in SPRINT raised the rates of hypotension, syncope, and acute kidney injury. More importantly, SPRINT used automated unattended office blood pressure measurement, a protocol that typically produces readings 5-10 mmHg lower than standard clinic readings. A target of below 120 mmHg in that context doesn't translate directly to the same number on your doctor's office monitor.

Tangential levers

Several interventions nudge blood pressure without being the core of the outcome evidence above. Magnesium adequacy correlates with modest reductions of around 2 mmHg [4]. Passive heat therapy, repeated sauna-style exposure, improved vascular function and blood pressure in an RCT [5]. Nicotinamide riboside (NR) has been examined in the context of exercise-related hypertension [6], though that line of research is more preliminary.

These interventions operate on a different scale than the antihypertensive evidence summarized above. A 2 mmHg shift from magnesium is not the same class of intervention as the 10-20 mmHg reductions driving the mortality numbers in [1] and [2].

What this means practically

Blood pressure is one of the few biomarkers where the causal chain from number to outcome to intervention has been stress-tested at scale. The evidence supports treating it seriously well below the thresholds historically considered "high", and supports continued optimization even in ranges once considered acceptable. How aggressively to pursue a lower target depends on individual risk tolerance and the side-effect profile of tighter control, which includes real risks of dizziness and kidney stress [3].

None of this constitutes a personal treatment recommendation. What it does is establish that blood pressure is not a passive bystander in aging and cardiovascular health. It's one of the clearest levers available.

References

1. Ettehad 2016, Lancet — BP lowering per 10 mmHg SBP (613,815 participants) · PubMed 26724178
2. BPLTTC 2021, Lancet — BP lowering per 5 mmHg, IPD meta (344,716) · PubMed 33933205
3. SPRINT 2015, NEJM — intensive BP <120 cuts events + mortality (HR 0.75/0.73) · PubMed 26551272
4. Zhang et al. 2016, Hypertension — magnesium & blood pressure · PubMed 27402922
5. Brunt et al. 2016, J Physiol — passive heat therapy & vascular function · PubMed 27270841
6. Lin AL et al. 2025 (GeroScience) — NR 1000mg + exercise vs placebo + exercise in sedentary adults ≥55; systolic BP null; trend toward nighttime BP… · PubMed 40770531